Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* OI diagnosis~* increased risk of fracture: either has a history of at least 1 radiographically confirmed, non-traumatic or low impact fracture plus low bone mineral density (BMD) or has very low BMD with or without a history of fractures.~Exclusion Criteria:~* Any bisphosphonate use within one year of enrollment

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Daily (Type: PLACEBO_COMPARATOR): placebo tablet, once a day for one year then for two years open label risedronate
- Risedronate Daily (Type: EXPERIMENTAL): risedronate tablet, once a day for one year then for two years open label risedronate once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).